eligibility_summary
Adults 18–75 with histologically/cytologically confirmed locally advanced/metastatic solid tumors (e.g., NSCLC, NPC), measurable disease (RECIST 1.1), ECOG 0–1, life expectancy ≥3 mo, LVEF ≥50%, adequate organ/coag/renal function, tumor tissue available. Exclude: recent anti-cancer/immunomod drugs or trials, severe cardiac/QT, grade ≥3 lung disease/ILD, uncontrolled HTN, CNS mets, autoimmune disease, major effusions, active infection (HIV/TB/HBV/HCV), transplant, contraception required, Cohort A: METex14 excluded.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT05956587 (Phase II) tests two IV drugs in advanced NSCLC/NPC and other solid tumors: 1) SI-B003: a monoclonal antibody immunotherapy (checkpoint inhibitor, specific target not specified in the registry). Mechanism: blocks an immune checkpoint to restore antitumor T‑cell activity. Type: immune checkpoint inhibitor mAb. 2) BL-B01D1 (iza-bren, izalontamab brengitecan, BMS-986507): an antibody–drug conjugate. Mechanism: the antibody binds a tumor-associated surface antigen on cancer cells, is internalized, and releases brengitecan (a topoisomerase I–inhibitor payload) to induce DNA damage and apoptosis. Type: ADC with topo I inhibitor payload. Targeted cells/pathways: antigen-positive tumor cells (for ADC), DNA damage/repair pathways via topo I inhibition, tumor-infiltrating T cells via checkpoint blockade (SI-B003), affecting the PD-1/PD-L1 axis or similar checkpoint pathway. Combination aims for direct tumor kill plus immune activation.